Cargando…
Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a progressive pulmonary disease that almost exclusively affects women. LAM cells migrate to the lungs, where they cause cystic destruction of lung parenchyma. Mutations in TSC1 or TSC2 lead to the activation of the mammalian target of rapamycin complex-1, a kinase t...
Autores principales: | Li, Xiangke, Liu, Xiaolei, Zhang, Linda, Li, Chenggang, Zhang, Erik, Ma, Wang, Fan, Qingxia, Yu, Jane J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482682/ https://www.ncbi.nlm.nih.gov/pubmed/28410230 http://dx.doi.org/10.18632/oncotarget.16695 |
Ejemplares similares
-
Glutaredoxin‐1 promotes lymphangioleiomyomatosis progression through inhibiting Bim‐mediated apoptosis via COX2/PGE2/ERK pathway
por: Feng, Ya, et al.
Publicado: (2023) -
Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis
por: Li, Chenggang, et al.
Publicado: (2014) -
The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis
por: Miller, Suzanne, et al.
Publicado: (2018) -
Management of lymphangioleiomyomatosis
por: Taveira-DaSilva, Angelo M., et al.
Publicado: (2014) -
Lymphangioleiomyomatosis (LAM)
Publicado: (2017)